Previous studies have reported impaired Ca2+ signalling in NK cells from CFS/ME patients demonstrated through changes to ERK1/2 and mitogen-activated protein kinase (MAPK) pathways (Chacko et al., 2016; Huth et al., 2016b). The gene discussed is MAPK3; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.